vs
Fastenal（FAST）与徕博科（LH）财务数据对比。点击上方公司名可切换其他公司
徕博科的季度营收约是Fastenal的1.7倍（$3.5B vs $2.0B），Fastenal净利率更高（14.5% vs 4.7%，领先9.8%），徕博科同比增速更快（5.6% vs 3.5%），徕博科自由现金流更多（$490.3M vs $308.2M），过去两年徕博科的营收复合增速更高（5.2% vs 2.9%）
Fastenal是1967年成立的美国上市企业，总部位于明尼苏达州威诺纳，是北美最大的紧固件分销商，同时也是工业和建筑用品的主流供应商，可提供货柜备货、智能售货柜、库存管理、物流配送等一站式供应链解决方案。
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
FAST vs LH — 直观对比
营收规模更大
LH
是对方的1.7倍
$2.0B
营收增速更快
LH
高出2.1%
3.5%
净利率更高
FAST
高出9.8%
4.7%
自由现金流更多
LH
多$182.1M
$308.2M
两年增速更快
LH
近两年复合增速
2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.0B | $3.5B |
| 净利润 | $293.9M | $164.7M |
| 毛利率 | 44.3% | 28.2% |
| 营业利润率 | 18.9% | 7.6% |
| 净利率 | 14.5% | 4.7% |
| 营收同比 | 3.5% | 5.6% |
| 净利润同比 | -1.6% | 14.9% |
| 每股收益（稀释后） | $-0.01 | $1.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FASTLH
| Q1 26 | $2.0B | — | ||
| Q4 25 | $2.0B | $3.5B | ||
| Q3 25 | $2.1B | $3.6B | ||
| Q2 25 | $2.1B | $3.5B | ||
| Q1 25 | $2.0B | $3.3B | ||
| Q4 24 | $1.8B | $3.3B | ||
| Q3 24 | $1.9B | $3.3B | ||
| Q2 24 | $1.9B | $3.2B |
净利润FASTLH
| Q1 26 | $293.9M | — | ||
| Q4 25 | $293.9M | $164.7M | ||
| Q3 25 | $335.5M | $261.1M | ||
| Q2 25 | $330.3M | $237.9M | ||
| Q1 25 | $298.7M | $212.8M | ||
| Q4 24 | $262.1M | $143.4M | ||
| Q3 24 | $298.1M | $169.3M | ||
| Q2 24 | $292.7M | $205.3M |
毛利率FASTLH
| Q1 26 | 44.3% | — | ||
| Q4 25 | 44.3% | 28.2% | ||
| Q3 25 | 45.3% | 28.8% | ||
| Q2 25 | 45.3% | 29.7% | ||
| Q1 25 | 45.1% | 28.3% | ||
| Q4 24 | 44.8% | 26.9% | ||
| Q3 24 | 44.9% | 27.6% | ||
| Q2 24 | 45.1% | 28.8% |
营业利润率FASTLH
| Q1 26 | 18.9% | — | ||
| Q4 25 | 18.9% | 7.6% | ||
| Q3 25 | 20.7% | 11.1% | ||
| Q2 25 | 21.0% | 11.2% | ||
| Q1 25 | 20.1% | 9.7% | ||
| Q4 24 | 18.9% | 6.5% | ||
| Q3 24 | 20.3% | 7.7% | ||
| Q2 24 | 20.2% | 9.2% |
净利率FASTLH
| Q1 26 | 14.5% | — | ||
| Q4 25 | 14.5% | 4.7% | ||
| Q3 25 | 15.7% | 7.3% | ||
| Q2 25 | 15.9% | 6.7% | ||
| Q1 25 | 15.2% | 6.4% | ||
| Q4 24 | 14.4% | 4.3% | ||
| Q3 24 | 15.6% | 5.2% | ||
| Q2 24 | 15.3% | 6.4% |
每股收益（稀释后）FASTLH
| Q1 26 | $-0.01 | — | ||
| Q4 25 | $-0.01 | $1.98 | ||
| Q3 25 | $0.29 | $3.12 | ||
| Q2 25 | $0.29 | $2.84 | ||
| Q1 25 | $0.52 | $2.52 | ||
| Q4 24 | $0.45 | $1.72 | ||
| Q3 24 | $0.52 | $2.00 | ||
| Q2 24 | $0.51 | $2.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $276.8M | $532.3M |
| 总债务越低越好 | $125.0M | — |
| 股东权益账面价值 | $3.9B | $8.6B |
| 总资产 | $5.1B | $18.4B |
| 负债/权益比越低杠杆越低 | 0.03× | — |
8季度趋势，按日历期对齐
现金及短期投资FASTLH
| Q1 26 | $276.8M | — | ||
| Q4 25 | $276.8M | $532.3M | ||
| Q3 25 | $288.1M | $598.1M | ||
| Q2 25 | $237.8M | $647.3M | ||
| Q1 25 | $231.8M | $369.4M | ||
| Q4 24 | $255.8M | $1.5B | ||
| Q3 24 | $292.2M | $1.5B | ||
| Q2 24 | $255.5M | $265.1M |
总债务FASTLH
| Q1 26 | $125.0M | — | ||
| Q4 25 | $125.0M | — | ||
| Q3 25 | $195.0M | — | ||
| Q2 25 | $230.0M | — | ||
| Q1 25 | $200.0M | — | ||
| Q4 24 | $200.0M | — | ||
| Q3 24 | $240.0M | — | ||
| Q2 24 | $235.0M | — |
股东权益FASTLH
| Q1 26 | $3.9B | — | ||
| Q4 25 | $3.9B | $8.6B | ||
| Q3 25 | $3.9B | $8.7B | ||
| Q2 25 | $3.8B | $8.5B | ||
| Q1 25 | $3.7B | $8.3B | ||
| Q4 24 | $3.6B | $8.1B | ||
| Q3 24 | $3.6B | $8.2B | ||
| Q2 24 | $3.5B | $8.0B |
总资产FASTLH
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.1B | $18.4B | ||
| Q3 25 | $5.1B | $18.3B | ||
| Q2 25 | $5.0B | $18.1B | ||
| Q1 25 | $4.9B | $17.6B | ||
| Q4 24 | $4.7B | $18.4B | ||
| Q3 24 | $4.7B | $18.6B | ||
| Q2 24 | $4.6B | $16.7B |
负债/权益比FASTLH
| Q1 26 | 0.03× | — | ||
| Q4 25 | 0.03× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.06× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.07× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $368.2M | $614.2M |
| 自由现金流经营现金流 - 资本支出 | $308.2M | $490.3M |
| 自由现金流率自由现金流/营收 | 15.2% | 13.9% |
| 资本支出强度资本支出/营收 | 3.0% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.25× | 3.73× |
| 过去12个月自由现金流最近4个季度 | $1.2B | $1.2B |
8季度趋势，按日历期对齐
经营现金流FASTLH
| Q1 26 | $368.2M | — | ||
| Q4 25 | $368.2M | $614.2M | ||
| Q3 25 | $386.9M | $387.2M | ||
| Q2 25 | $278.6M | $620.6M | ||
| Q1 25 | $262.2M | $18.5M | ||
| Q4 24 | $282.8M | $777.2M | ||
| Q3 24 | $296.9M | $277.3M | ||
| Q2 24 | $258.0M | $561.1M |
自由现金流FASTLH
| Q1 26 | $308.2M | — | ||
| Q4 25 | $308.2M | $490.3M | ||
| Q3 25 | $326.6M | $280.5M | ||
| Q2 25 | $209.3M | $542.7M | ||
| Q1 25 | $206.5M | $-107.5M | ||
| Q4 24 | $222.6M | $665.1M | ||
| Q3 24 | $237.5M | $161.5M | ||
| Q2 24 | $201.9M | $432.9M |
自由现金流率FASTLH
| Q1 26 | 15.2% | — | ||
| Q4 25 | 15.2% | 13.9% | ||
| Q3 25 | 15.3% | 7.9% | ||
| Q2 25 | 10.1% | 15.4% | ||
| Q1 25 | 10.5% | -3.2% | ||
| Q4 24 | 12.2% | 20.0% | ||
| Q3 24 | 12.4% | 4.9% | ||
| Q2 24 | 10.5% | 13.4% |
资本支出强度FASTLH
| Q1 26 | 3.0% | — | ||
| Q4 25 | 3.0% | 3.5% | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 3.3% | 2.2% | ||
| Q1 25 | 2.8% | 3.8% | ||
| Q4 24 | 3.3% | 3.4% | ||
| Q3 24 | 3.1% | 3.5% | ||
| Q2 24 | 2.9% | 4.0% |
现金转化率FASTLH
| Q1 26 | 1.25× | — | ||
| Q4 25 | 1.25× | 3.73× | ||
| Q3 25 | 1.15× | 1.48× | ||
| Q2 25 | 0.84× | 2.61× | ||
| Q1 25 | 0.88× | 0.09× | ||
| Q4 24 | 1.08× | 5.42× | ||
| Q3 24 | 1.00× | 1.64× | ||
| Q2 24 | 0.88× | 2.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FAST
| Reportable Segment Aggregation Before Other Operating Segment | $1.8B | 90% |
| Other | $211.2M | 10% |
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
